News | Radiation Therapy | February 09, 2016

UCLA study finds HPV-negative cancer cells are more easily converted into head and neck cancer stem cells than those that are HPV-positive

radiation therapy, head and neck cancers, HPV status, UCLA study

February 9, 2016 — Head and neck cancers that test positive for the herpes papilloma virus (HPV) are known to respond more favorably to radiation therapy than those that test HPV-negative, but an explanation for these differences has remained elusive.

Now, UCLA scientists have shown for the first time that radiation treatment transforms cancer cells into head and neck cancer stem cells — which are known to be resistant to radiation therapy — more effectively when the cancer tests negative for HPV. These findings shed light on why some head and neck cancers fair much worse after radiation therapy despite optimum treatment regimens.

Led by UCLA Jonsson Comprehensive Cancer Center members Erina Vlashi, M.D., and Frank Pajonk, M.D., the study showed the non-stem cancer cells that survived radiation therapy had the ability to convert into cancer stem cells, which have shown to be more resistant to radiation treatment. The process, called “radiation-induced conversion,” happened at a higher frequency in HPV-negative head and neck cancers, providing a clinically relevant explanation for the differences in response to radiation therapy.

The team reviewed 162 head and neck squamous carcinomas (HNSCCs) patients over a two-year period, and confirmed that their outcomes were correlated with their HPV status.

The study was built upon Vlashi and Pajonk’s previous research in breast cancer, which showed that therapy-resistant cancer cells are more prone to therapy-induced conversion depending on the aggressiveness of the type of breast cancer.

While radiation therapy may have some unwanted consequences, it remains an indispensable treatment for people with the disease. Further studies are currently underway to identify drugs that can interfere with radiation-induced conversion, said Vlashi.

The scientists hope this research will lead to a new type of combination treatment to improve the response of head and neck tumor cells to radiation therapy.

The study is available online in the International Journal of Radiation Oncology, Biology and Physics.

For more information: www.redjournal.org


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
Subscribe Now